Genitourinary Cancers Symposium (ASCO GU) | Conference

ASCO GU 2021 News: Dr. Petros Grivas and Dr. Arlene Siefker-Radtke

February 15th 2021

Cabozantinib Significantly Prolongs PFS Over Sunitinib in Papillary RCC

February 14th 2021

February 13, 2021 - Cabozantinib resulted in a statistically significant and clinically meaningful prolongation of progression-free survival compared with sunitinib in patients with metastatic papillary renal cell carcinoma.

Lenvatinib Plus Pembrolizumab Improves Survival, Responses Versus Sunitinib in Advanced RCC

February 13th 2021

February 13, 2021 - Lenvatinib in combination with pembrolizumab resulted in improved overall survival, progression-free survival, and objective response rate over sunitinib in the frontline treatment of patients with advanced renal cell carcinoma.

Belzutifan/Cabozantinib Shows Promising Early Antitumor Activity in Advanced Clear Cell RCC

February 13th 2021

February 13, 2021 - Belzutifan used in combination with cabozantinib shrank tumors for 88% of patients and the disease control rate was 90% for patients with previously treated advanced clear cell renal cell carcinoma.

Molecular Signatures Linked With Long-Term Response to Apalutamide in Nonmetastatic CRPC

February 13th 2021

February 13, 2021 - Certain molecular signatures at baseline were found to be independently linked with long-term response to apalutamide in patients with nonmetastatic castration-resistant prostate cancer.

BCG Plus N-803 Elicits Positive Responses, Tolerability in BCG-Unresponsive NMIBC CIS

February 13th 2021

February 13, 2021 - Bacillus calmette-guérin plus N-803 demonstrated promising responses with a tolerable safety profile when used in patients with BCG-unresponsive, non–muscle-invasive bladder cancer carcinoma in situ

Reduction in PSA Screening Associated with Increased Incidence of Metastatic Prostate Cancer in the United States

February 13th 2021

February 13, 2021 - Reductions in prostate-specific antigen screening are likely responsible for the recent increase in metastatic prostate cancer cases in the United States.

PSMA PET Imaging Agent 18F-DCFPyL Demonstrates High CLR and PPV

February 13th 2021

February 13, 2021 - 18F-DCFPyL, an investigational prostate-specific membrane antigen PET imaging agent, was found to detect and localize metastatic lesions with a high correct localization rate and positive predictive value.

ASCO GU 2021 News: Drs. Bradley McGregor, David Braun, and

February 13th 2021

Dr. Piliè on Impact of Adiposity on Response to Androgen Signaling Inhibition in mCRPC

February 13th 2021

Patrick Pilie, MD, discusses the impact of adiposity on response to androgen signaling inhibition in patients with metastatic castration-resistant prostate cancer.

Dr. Dorff on the Benefit of Bright White Light Therapy on Obese Frailty in Prostate Cancer

February 13th 2021

Tanya Dorff, MD, discusses the effects of bright white light therapy on obese frailty in older men with prostate cancer.

Enfortumab Vedotin Shows Superior Efficacy Over Chemo in Previously Treated Urothelial Carcinoma

February 13th 2021

February 13, 2021 - Enfortumab vedotin was found to have superior efficacy over chemotherapy when used in patients with advanced urothelial carcinoma who had received prior platinum-based chemotherapy and PD-1/L1 inhibition.

Apalutamide Demonstrates Sustained Survival Benefit in mCSPC

February 13th 2021

February 13, 2021 - Treatment with apalutamide plus androgen-deprivation therapy reduced the risk of death by 35% versus ADT alone in patients with metastatic castration-sensitive prostate cancer.

Adjuvant Nivolumab Improves DFS in Patients With MIUC

February 13th 2021

February 13, 2021 - Nivolumab following surgery extended disease-free survival compared with placebo for patients with muscle-invasive urothelial carcinoma.

Enfortumab Vedotin Showcases Impressive Safety, Efficacy in Cisplatin-Ineligible Urothelial Cancer

February 13th 2021

February 12, 2021 - Enfortumab vedotin elicited the highest response rates observed for any regimen examined in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer who received prior PD-1/PD-L1 inhibitors.

Cabozantinib Displays Significant Intracranial Activity in Metastatic RCC

February 13th 2021

February 12, 2021 - Cabozantinib demonstrated significant intracranial and extracranial responses in patients with metastatic renal cell carcinoma who have brain metastases.

Dr. Bergerot on Improved HRQoL With a Higher Starting Dose of Lenvatinib Plus Everolimus in RCC

February 13th 2021

Cristiane Bergerot PhD, MS, BS, discusses how a higher starting dose of lenvatinib, to be combined with everolimus, can improve health-related quality of life in patients with renal cell carcinoma, as demonstrated in a phase 2 open-label trial.

Frontline Nivolumab/Cabozantinib Maintains Survival Benefit Over Sunitinib in Advanced RCC

February 13th 2021

February 12, 2021 - The combination of nivolumab and cabozantinib continued to showcase a superior survival benefit over single-agent sunitinib when used as first-line treatment in patients with advanced renal cell carcinoma.

Dr. Efstathiou on the rPFS Benefit Achieved With Apalutamide Regimen in mCRPC

February 12th 2021

Eleni Efstathiou, MD, discusses the key findings of the placebo-controlled, double-blind phase 3 ACIS study of apalutamide and abiraterone acetate plus prednisone versus prednisone alone in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer.

Tivozanib Reduces Symptomatic Burden and Toxicity in RCC

February 12th 2021

February 12, 2021 - Tivozanib led to a significantly greater quality-adjusted time without symptoms of disease and toxicity as third- or fourth-line therapy versus sorafenib in patients with metastatic renal cell carcinoma.